partner of NOB1 homologGenealiases: KHRBP1 · RRP20
Q-omics provides the consensus-scored PNO1 profile across patient tissues and cancer cell-line models. PNO1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PNO1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PNO1 protein abundance shows 37,669 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where PNO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNO1 survival associations across molecular data types. PNO1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNO1 RNA expression–survival associations across cancer types. High PNO1 expression shows unfavorable associations in ACC, LIHC, HNSC, MESO, KIRP and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PNO1 RNA expression.
This table summarizes PNO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PNO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNO1 shows higher tumor expression in HNSC, COAD, LIHC, STAD, LUAD and KIRC. The HNSC box plot shows higher PNO1 RNA expression in tumor versus normal tissue (log2 FC = +1.439, t-test p < 0.001).
This table shows molecular features associated with PNO1 in patient tissues and cancer cell lines. In patient samples, PNO1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PNO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
